Quick Takeaways
- Sands Capital Alternatives, LLC filed SCHEDULE 13G/A for Acumen Pharmaceuticals, Inc. Common Stock, par value $0.0001 per share (ABOS).
- Disclosed ownership: 5.6%.
- Date of event: 30 Jun 2025.
Sands Capital Alternatives, LLC - 30 Jun 2025 SCHEDULE 13G/A Report for Acumen Pharmaceuticals, Inc. Common Stock, par value $0.0001 per share (ABOS)
- Filing Manager
- Sands Capital Alternatives, LLC
- Reporting Manager
- Sands Capital Alternatives, LLC
- Symbol
- ABOS
- Shares outstanding
- 61,019,196 shares
- Disclosed Ownership
- 3,417,075 shares
- Ownership
- 5.6%
- Form type
- SCHEDULE 13G/A
- Filing time
- 13 Aug 2025, 11:27:31 UTC
- Date of event
- 30 Jun 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Sands Capital Alternatives, LLC disclosed 5.6% ownership in Acumen Pharmaceuticals, Inc. Common Stock, par value $0.0001 per share (ABOS) on 30 Jun 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 13 Aug 2025, 11:27.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (5)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Sands Capital Alternatives, LLC | 5.6% | 3,417,075 | 0 | 3,417,075 | /s/ Jonathan Goodman | Jonathan Goodman, General Counsel | |
| Sands Capital Ventures Discovery Fund III, L.P. | 1.9% | 1,124,729 | 0 | 1,124,729 | /s/ Jonathan Goodman | Jonathan Goodman, General Counsel of the General Partner of Sands Capital Ventures Discovery Fund III, L.P. | |
| Sands Capital Global Venture Fund II, L.P. | 1.9% | 1,146,173 | 0 | 1,146,173 | /s/ Jonathan Goodman | Jonathan Goodman, General Counsel of the GP of the GP of Sands Capital Global Venture Fund II, L.P. | |
| Sands Capital Life Sciences Pulse Fund, LLC | 1.9% | 1,146,173 | 0 | 1,146,173 | /s/ Jonathan Goodman | Jonathan Goodman, General Counsel | |
| SANDS FRANK M. | 5.6% | 3,417,075 | 0 | 3,417,075 | /s/ Frank M. Sands | Frank M. Sands |